Works by Xing, Baocai


Results: 28
    1
    2
    3
    4
    5

    Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.

    Published in:
    Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1897, doi. 10.1007/s00262-021-03102-3
    By:
    • Gong, Jifang;
    • Cao, Junning;
    • Zhang, Qingyuan;
    • Xu, Nong;
    • Zhao, Yanqiu;
    • Xing, Baocai;
    • Miao, Zhanhui;
    • Wu, Yilong;
    • Pan, Hongming;
    • Gao, Quanli;
    • Li, Xingya;
    • Liu, Baorui;
    • Li, Wei;
    • Pei, Zhidong;
    • Xia, Hongqiang;
    • Qi, Qinzhou;
    • Dai, Hangjun;
    • Shi, Qingmei;
    • Yang, Jianxin;
    • Li, Jin
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28